138 related articles for article (PubMed ID: 37694290)
1. Focal myocarditis associated with immune checkpoint inhibitor therapy.
Hayashizaki M; Omote K; Tsuneta S; Nagai T; Anzai T
Eur Heart J Cardiovasc Imaging; 2023 Nov; 24(12):e308. PubMed ID: 37694290
[No Abstract] [Full Text] [Related]
2. Immune checkpoint inhibitor-related myositis and myocarditis with multiple myositis-specific/-associated antibodies.
Isa M; Hongo Y; Sakamoto N; Yamazaki K; Takazaki H; Asakuma J; Ikewaki K; Suzuki K
J Neurol Sci; 2023 Jan; 444():120528. PubMed ID: 36565689
[No Abstract] [Full Text] [Related]
3. The potential of auto-antigen-guided treatment of immune checkpoint inhibitor-mediated myocarditis.
Zhu H; Huang YV; Wu SM
Med; 2023 Jan; 4(1):13-14. PubMed ID: 36640753
[TBL] [Abstract][Full Text] [Related]
4. [A case report of immune checkpoint inhibitor-induced myocarditis].
Liao HL; Chen DD; Pan Y; Liu ZJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jul; 50(7):710-712. PubMed ID: 35856230
[TBL] [Abstract][Full Text] [Related]
5. Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis.
Xu Y; Song Y; Liu X; Shi Y; Liu Y; Qian H; Gao X; Chen M; Pan R; Zhao J; Zhong W; Wu W; Wang M
Cancer Commun (Lond); 2022 Sep; 42(9):902-905. PubMed ID: 35678260
[No Abstract] [Full Text] [Related]
6. Immune Checkpoint Inhibitor-Induced Myocarditis With Concurrent Myasthenia Gravis.
Kuniyoshi J; Huang R; Choi H; Bernas M; Techasatian W; Nishimura Y
Can J Cardiol; 2023 Nov; 39(11):1646-1648. PubMed ID: 37330137
[No Abstract] [Full Text] [Related]
7. Combined checkpoint inhibitor-associated myocarditis and pulmonary vasculitis mimicking acute pulmonary embolism.
Baldetti L; Melillo F; Beneduce A; Camici PG
Eur Heart J Cardiovasc Imaging; 2019 Feb; 20(2):243. PubMed ID: 30535006
[No Abstract] [Full Text] [Related]
8. New biomarker-based strategy screens for myocarditis after immune checkpoint inhibitor treatment.
Nierengarten MB
Cancer; 2023 May; 129(9):1304. PubMed ID: 37029508
[No Abstract] [Full Text] [Related]
9. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.
Thibault C; Vano Y; Soulat G; Mirabel M
Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497
[No Abstract] [Full Text] [Related]
11. Immune checkpoint inhibitor-induced myocarditis not visible with cardiac magnetic resonance imaging but detected with PET-CT: a case report.
Arponen O; Skyttä T
Acta Oncol; 2020 Apr; 59(4):490-492. PubMed ID: 31920130
[No Abstract] [Full Text] [Related]
12. Sinus Node Dysfunction Co-occurring with Immune Checkpoint Inhibitor-associated Myocarditis.
Nishikawa T; Kunimasa K; Ohta-Ogo K; Ikeda Y; Yasui T; Shioyama W; Oka T; Honma K; Hatakeyama K; Kumagai T; Fujita M
Intern Med; 2022 Jul; 61(14):2161-2165. PubMed ID: 35283377
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.
Palaskas N; Lopez-Mattei J; Durand JB; Iliescu C; Deswal A
J Am Heart Assoc; 2020 Jan; 9(2):e013757. PubMed ID: 31960755
[No Abstract] [Full Text] [Related]
14. Immunotherapy-Associated Myocarditis.
Spisarová M
Klin Onkol; 2020; 33(1):20-22. PubMed ID: 32075384
[TBL] [Abstract][Full Text] [Related]
15. Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice.
Tang X; Li Y; Huang H; Shi R; Shen LT; Qian WL; Yang ZG
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8345-8357. PubMed ID: 37076643
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms.
Champion SN; Stone JR
Mod Pathol; 2020 Jan; 33(1):99-108. PubMed ID: 31534205
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases.
Atallah-Yunes SA; Kadado AJ; Kaufman GP; Hernandez-Montfort J
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1527-1557. PubMed ID: 31028541
[TBL] [Abstract][Full Text] [Related]
18. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
Prevel R; Colin G; Calès V; Renault PA; Mazieres J
Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
[TBL] [Abstract][Full Text] [Related]
19. Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors.
Arangalage D; Delyon J; Lermuzeaux M; Ekpe K; Ederhy S; Pages C; Lebbé C
Ann Intern Med; 2017 Nov; 167(9):683-684. PubMed ID: 28869988
[No Abstract] [Full Text] [Related]
20. Fatal myocarditis after the first dose of nivolumab.
Zomborska E; Kasperova S; Slopovsky J; Pazderová N; Kasperova B; Penz P; Nyitrayová O; Salek T; Porsok S; Mladosievicova B; Mego M
Klin Onkol; 2022; 35(6):486-492. PubMed ID: 36513516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
